Efficacy and Safety of Sintilimab Combined Intraperitoneal and Intravenous Paclitaxel Plus Oral S-1 in Gastric Cancer Patients With Peritoneal Metastasis

NCT05204173 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Gastric Cancer Stage IV
Peritoneal Metastases

Interventions

DRUG: sintilimab, paclitaxel and S-1

Sponsor

Ruijin Hospital